Inhibition of Murine AIDS by Combination of AZT and Dideoxycytidine 5′-Triphosphate

Journal of Acquired Immune Deficiency Syndromes

Volumn 12, Issue 2, 1996, Pages 164-173

  Fraternale, Alessandra ^a   Casabianca, Anna ^a   Rossi, Luigia ^a   Chiarantini, Laura ^a   Brandi, Giorgio ^a   Aluigi, Gianfranca ^a   Schiavano, Giuditta F ^a   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

AZT; Combination therapy; ddCTP; Murine retrovirus induced immunodeficiency

Indexed keywords

2',3' DIDEOXYCYTIDINE 5' TRIPHOSPHATE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; DEOXYCYTOSINE NUCLEOTIDES; DNA PRIMERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; LEUKEMIA VIRUS, MURINE; LYMPH NODES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; POLYMERASE CHAIN REACTION; PROVIRUSES; SPLEEN; ZIDOVUDINE;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0030007660     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199606010-00010     Document Type: Article

References (32)

1. Hirsch M, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993;328:1686-95.
2. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990;249:1533-44.
3. Eron JJ, Johnson VA, Merrill DP, Chon TC, Hirsch MS. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-d/deoxycytidine in vitro. Antimicrob Agents Chemother 1992;36:1559-62.
4. Mazzulli T, Rusconi S, Merrill DP, et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994;38:656-61.
5. Rusconi S, Merrill DP, Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 1994;170:1361-6.
6. Jacobson MA, van der Horst C, Causey DM, Dehlinger M, Hafner R, Mills J. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG protocol 053). J Infect Dis 1991;163:1219-22.
7. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Intern Med 1992;116:13-20.
8. Showron G, Bozzette SA, Lim I, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993;118:321-30.
9. Yarchoan R, Lietzan JA, Nguyen BY, et al. A randomized pilot study of alternating simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9-17.
10. Gartner S, Marcovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-9.
11. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophages by human T/lymphotropic virus type III. J Clin Invest 1986;77:12-5.
12. Aziz DC, Hanna Z, Jolicoeur P. Severe immunodeficiency disease induced by a defective murine leukemia virus. Nature 1989;338:505-8.
13. Chattopadhyay SK, Sengupta DN, Fredrickson TN, Morse HC III, Hartley JW. Characteristics and contributions of defective, ecotropic and mink cell focus-inducing viruses in a retrovirus induced immunodeficiency syndrome of mice. J Virol 1991;65:4232-41.
14. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J 1991;5:2398-405.
15. Morse HC III, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 1992;6:607-21.
16. Basham T, Rios CD, Holdener T, Merigan TC. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis 1990;161:1006-9.
17. Eiseman JL, Yetter RA, Fredrickson TN, Shapiro SG, MacAuley C, Bilello JA. Effect of 3′ azidothymidine administered in drinking water or by continuous infusion on the development of MAIDS. Antiviral Res 1991;16:307-26.
18. Bilello JA, Kork JJ, MacAuley C, Fredrickson TN, Yetter RA, Eiseman JL. ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MnLV-infected macrophage-monocytes. J Acquir Immune Defic Syndr 1992;5:571-6.
19. Magnani M, Casabianca A, Rossi L, et al. Inhibition of HIV-1 and LP-BM5 replication in macrophages by dideoxycytidine and dideoxycytidine-5′-triphosphate. Antiviral Chem Chemother 1995;6:312-3..
20. Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA 1992;89:6477-81.
21. Hosier DE, Yetter RA, Morse HC III. Functional T lymphocytes are required for a murine retrovirus induced immunodeficiency disease (MAIDS). J Exp Med 1987;165:1737-42.
22. Rossi L, Brandi G, Fraternale A, Schiavano GF, Chiarantini L, Magnani M. Inhibition of murine retrovirus induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′-triphosphate. J Acquir Immune Defic Syndr 1993;6:1179-86.
23. Kurdi-Haidar B, Mason PJ, Berrebi A, et al. Origin and spread of the glucose-6-phosphate dehydrogenase variant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet 1990;47:1013-19.
24. Brandi G, Casabianca A, Schiavano GF, et al. Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. Antiviral Chem Chemother 1995;6:153-61.
25. Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel HK. 9-(2-Phosphonylmethoxyethyl) adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 1989;33:1864-8.
26. Ohnota H, Okada Y, Ushijima H, Kitamura T, Komuro K, Mizuoki T. 3′ Azido-3′ -deoxylhymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia virus, a possible animal model for antiretroviral drug screening. Antimicrob Agents Chemother 1990;34:605-9.
27. Magnani M, Rossi L. Fraternale A, et al. FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5′-triphosphate. Vet Immun Immunopathol 1995;46:151-8.
28. Magnani M, Rossi L, Fraternale A, et al. Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by ddCTP-loaded erythrocytes. AIDS Res Hum Retroviruses 1994;10:1179-86.
29. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxynosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
30. Perno CF, Yachoan R, Balzarini J, et al. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res 1992;17:289-304.
31. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988;37:893-903.
32. Brandi G, Carnevali A, Rossi L, Fraternale A, Schiavano GF, Magnani M. Effect of antiviral treatments on the bone marrow in murine AIDS. Blood Cells Mol Dis 1995;21:109-18.